FDA approves Bristol Myers Squibb’s ZEPOSIA oral treatment for relapsing forms of multiple sclerosis

This article was originally published here

ZEPOSIA, an oral medication taken once daily, is the only approved sphingosine-1-phosphate (S1P) receptor modulator that offers RMS patients an initiation with no genetic test and no label-based

The post FDA approves Bristol Myers Squibb’s ZEPOSIA oral treatment for relapsing forms of multiple sclerosis appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply